Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by stock analysts at TheStreet from a “b-” rating to a “c+” rating in a research note issued to investors on Thursday.

A number of other research analysts have also recently issued reports on the stock. Citigroup cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $480.00 to $380.00 in a report on Friday. J P Morgan Chase & Co restated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday. BTIG Research decreased their price objective on shares of Regeneron Pharmaceuticals from $520.00 to $480.00 and set a “buy” rating for the company in a report on Tuesday. BMO Capital Markets set a $444.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Monday, November 27th. Finally, Evercore ISI decreased their price objective on shares of Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating for the company in a report on Thursday, November 16th. Two research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $467.84.

Regeneron Pharmaceuticals (NASDAQ REGN) opened at $373.47 on Thursday. The stock has a market cap of $38,877.88, a P/E ratio of 31.33, a P/E/G ratio of 1.42 and a beta of 1.54. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. Regeneron Pharmaceuticals has a 1-year low of $340.09 and a 1-year high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.83 by $0.16. The firm had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The business’s revenue for the quarter was up 23.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.13 earnings per share. equities analysts forecast that Regeneron Pharmaceuticals will post 13.55 EPS for the current year.

In other news, CFO Robert E. Landry sold 189 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total value of $94,700.34. Following the sale, the chief financial officer now owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Michael S. Brown sold 1,500 shares of the business’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $475.00, for a total transaction of $712,500.00. The disclosure for this sale can be found here. Insiders sold 4,352 shares of company stock valued at $2,037,772 in the last quarter. Corporate insiders own 10.80% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Public Employees Retirement System of Ohio lifted its position in shares of Regeneron Pharmaceuticals by 0.4% in the third quarter. Public Employees Retirement System of Ohio now owns 54,532 shares of the biopharmaceutical company’s stock worth $24,382,000 after purchasing an additional 244 shares in the last quarter. Americafirst Capital Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth $700,000. Moors & Cabot Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth $217,000. IFM Investors Pty Ltd bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth $979,000. Finally, Fieldpoint Private Securities LLC raised its position in Regeneron Pharmaceuticals by 285.3% during the third quarter. Fieldpoint Private Securities LLC now owns 1,021 shares of the biopharmaceutical company’s stock worth $457,000 after acquiring an additional 756 shares in the last quarter. 69.47% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Regeneron Pharmaceuticals (REGN) Stock Rating Lowered by TheStreet” was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/12/02/regeneron-pharmaceuticals-regn-stock-rating-lowered-by-thestreet.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.